Skip to content

A multicenter, randomized, controlled trial of Qingyu Powder in the treatment of mild to moderate active ulcerative colitis

A multicenter, randomized, controlled trial of Qingyu Powder in the treatment of mild to moderate active ulcerative colitis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003558
Enrollment
Unknown
Registered
2020-08-13
Start date
2020-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

Experimental group:Qingyusan

Sponsors

Shuguang Hospital affiliated to Shanghai University of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) accord with the diagnostic standard of western medicine for ulcerative colitis; 2) the selected patients were mild to moderate ulcerative colitis (total Mayo score = 310); 3) Aged 18-65 years old; 4) agree to participate in this study and sign the informed letter at the same time.

Exclusion criteria

Exclusion criteria: (1) infectious colitis such as bacillary dysentery, amoebic dysentery, chronic schistosomiasis, intestinal tuberculosis, Crohn's disease and ischemic intestine; Patients with inflammatory and radiation enteritis; (2) there are serious complications such as local stenosis, intestinal obstruction, intestinal perforation, toxic colonic dilatation, massive hemorrhage, colon cancer and rectal cancer; (3) patients with other primary and secondary infectious diseases, such as cholecystitis, pneumonia, etc.; (4) patients with serious diseases of cardiovascular, hepatobiliary, lung, kidney and blood system; (5) Women during pregnancy and lactation; (6) patients with disabilities prescribed by law (blindness, deafness, mute, mental retardation, physical disability); (7) patients with severe ulcerative colitis (Mayo=11~12 score); or patients with complications.

Design outcomes

Primary

MeasureTime frame
Total Mayo score;Mayo endoscopic score;

Secondary

MeasureTime frame
Fecal calcitonin;Score of curative effect of TCM syndrome;Mucosal histology;ESR;Fecal routine and occult blood;CRP;SIBDQ;

Countries

China

Contacts

Public ContactDou Danbo

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

doudanbo@shutcm.edu.cn+86 18918044023

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026